CA2909479A1 - Method of determining the fraction of fetal dna in maternal blood using hla markers - Google Patents
Method of determining the fraction of fetal dna in maternal blood using hla markers Download PDFInfo
- Publication number
- CA2909479A1 CA2909479A1 CA2909479A CA2909479A CA2909479A1 CA 2909479 A1 CA2909479 A1 CA 2909479A1 CA 2909479 A CA2909479 A CA 2909479A CA 2909479 A CA2909479 A CA 2909479A CA 2909479 A1 CA2909479 A1 CA 2909479A1
- Authority
- CA
- Canada
- Prior art keywords
- hla
- maternal
- exon
- allele
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000008774 maternal effect Effects 0.000 title claims abstract description 262
- 230000001605 fetal effect Effects 0.000 title claims abstract description 151
- 238000000034 method Methods 0.000 title claims abstract description 149
- 210000004369 blood Anatomy 0.000 title claims abstract description 39
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 108700028369 Alleles Proteins 0.000 claims abstract description 345
- 108700024394 Exon Proteins 0.000 claims description 70
- 108020004414 DNA Proteins 0.000 claims description 66
- 238000012163 sequencing technique Methods 0.000 claims description 65
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 claims description 60
- 150000007523 nucleic acids Chemical class 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 230000003321 amplification Effects 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 51
- 108091093088 Amplicon Proteins 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 210000003754 fetus Anatomy 0.000 claims description 47
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims description 44
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims description 44
- 101150034979 DRB3 gene Proteins 0.000 claims description 29
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 claims description 29
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 28
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 28
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 28
- 101150082328 DRB5 gene Proteins 0.000 claims description 27
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 27
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 27
- 101100117565 Oryza sativa subsp. japonica DRB4 gene Proteins 0.000 claims description 27
- 101100117569 Oryza sativa subsp. japonica DRB6 gene Proteins 0.000 claims description 27
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000011461 pre-eclampsia Diseases 0.000 claims description 16
- 238000007847 digital PCR Methods 0.000 claims description 11
- 230000004544 DNA amplification Effects 0.000 claims description 7
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 238000000638 solvent extraction Methods 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000002759 chromosomal effect Effects 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 123
- 210000002381 plasma Anatomy 0.000 description 23
- 230000008775 paternal effect Effects 0.000 description 22
- 238000001514 detection method Methods 0.000 description 20
- -1 DQA1 Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 239000011324 bead Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000003205 genotyping method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000012350 deep sequencing Methods 0.000 description 6
- 201000003883 Cystic fibrosis Diseases 0.000 description 5
- 108091092195 Intron Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000007403 mPCR Methods 0.000 description 5
- 238000007481 next generation sequencing Methods 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 4
- 210000002593 Y chromosome Anatomy 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012175 pyrosequencing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000012807 PCR reagent Substances 0.000 description 3
- 108091008109 Pseudogenes Proteins 0.000 description 3
- 102000057361 Pseudogenes Human genes 0.000 description 3
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 3
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 3
- 208000036878 aneuploidy Diseases 0.000 description 3
- 231100001075 aneuploidy Toxicity 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 2
- 102210010092 DQB1*03:01 Human genes 0.000 description 2
- 102210042965 DQB1*06:02 Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101150118346 HLA-A gene Proteins 0.000 description 2
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 2
- 108700005089 MHC Class I Genes Proteins 0.000 description 2
- 108700005092 MHC Class II Genes Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical group 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 101150046128 HLA-DQB1 gene Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 101000609261 Homo sapiens Plasminogen activator inhibitor 2 Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000010252 digital analysis Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361821620P | 2013-05-09 | 2013-05-09 | |
| US61/821,620 | 2013-05-09 | ||
| US201361861316P | 2013-08-01 | 2013-08-01 | |
| US61/861,316 | 2013-08-01 | ||
| PCT/EP2014/059348 WO2014180910A1 (en) | 2013-05-09 | 2014-05-07 | Method of determining the fraction of fetal dna in maternal blood using hla markers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2909479A1 true CA2909479A1 (en) | 2014-11-13 |
Family
ID=50680043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2909479A Abandoned CA2909479A1 (en) | 2013-05-09 | 2014-05-07 | Method of determining the fraction of fetal dna in maternal blood using hla markers |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150203914A1 (enExample) |
| EP (1) | EP2994538A1 (enExample) |
| JP (1) | JP2016516449A (enExample) |
| CN (1) | CN105189787A (enExample) |
| CA (1) | CA2909479A1 (enExample) |
| WO (1) | WO2014180910A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10131947B2 (en) * | 2011-01-25 | 2018-11-20 | Ariosa Diagnostics, Inc. | Noninvasive detection of fetal aneuploidy in egg donor pregnancies |
| CN108256296B (zh) * | 2017-12-29 | 2021-05-25 | 北京科迅生物技术有限公司 | 数据处理装置 |
| RU2681488C1 (ru) * | 2018-04-19 | 2019-03-06 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации | Способ прогнозирования состояния плода человека накануне родов |
| WO2021026828A1 (zh) * | 2019-08-14 | 2021-02-18 | 深圳华大基因股份有限公司 | 确定孕妇血液中胎儿核酸浓度的方法及设备 |
| PL445283A1 (pl) * | 2023-06-20 | 2024-12-23 | Instytut Centrum Zdrowia Matki Polki | Sposób nieinwazyjnej analizy płodowego DNA oraz frakcji płodu z wykorzystaniem reakcji multipleks digital PCR |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
| EP1599608A4 (en) * | 2003-03-05 | 2007-07-18 | Genetic Technologies Ltd | Identification of fetal DNA and fetal cell marker in maternal plasma or serum |
| US7867703B2 (en) | 2004-08-26 | 2011-01-11 | Agilent Technologies, Inc. | Element defined sequence complexity reduction |
| US8383338B2 (en) | 2006-04-24 | 2013-02-26 | Roche Nimblegen, Inc. | Methods and systems for uniform enrichment of genomic regions |
| US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
| US8315817B2 (en) | 2007-01-26 | 2012-11-20 | Illumina, Inc. | Independently removable nucleic acid sequencing system and method |
| EP2126765B1 (en) | 2007-01-26 | 2011-08-24 | Illumina Inc. | Nucleic acid sequencing system and method |
| JP2011500041A (ja) * | 2007-10-16 | 2011-01-06 | エフ．ホフマン−ラ ロシュ アーゲー | クローナルシークエンシングによる高分解能かつ高効率のｈｌａ遺伝子型決定法 |
| US20100261189A1 (en) * | 2008-10-03 | 2010-10-14 | Roche Molecular Systems, Inc. | System and method for detection of HLA Variants |
| HUE061110T2 (hu) * | 2009-11-05 | 2023-05-28 | Univ Hong Kong Chinese | Magzati genomelemzés anyai biológiai mintából |
| WO2012078792A2 (en) * | 2010-12-07 | 2012-06-14 | Stanford University | Non-invasive determination of fetal inheritance of parental haplotypes at the genome-wide scale |
-
2014
- 2014-05-07 CA CA2909479A patent/CA2909479A1/en not_active Abandoned
- 2014-05-07 EP EP14722211.1A patent/EP2994538A1/en not_active Withdrawn
- 2014-05-07 WO PCT/EP2014/059348 patent/WO2014180910A1/en not_active Ceased
- 2014-05-07 JP JP2016512364A patent/JP2016516449A/ja active Pending
- 2014-05-07 CN CN201480026232.2A patent/CN105189787A/zh active Pending
- 2014-05-09 US US14/273,763 patent/US20150203914A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150203914A1 (en) | 2015-07-23 |
| WO2014180910A1 (en) | 2014-11-13 |
| EP2994538A1 (en) | 2016-03-16 |
| JP2016516449A (ja) | 2016-06-09 |
| CN105189787A (zh) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9752189B2 (en) | Non-invasive early detection of solid organ transplant rejection by quantitative analysis of mixtures by deep sequencing of HLA gene amplicons using next generation systems | |
| JP6328934B2 (ja) | 非侵襲性出生前親子鑑定法 | |
| CN102575292B (zh) | 与疾病相关的kir单元型的测定 | |
| CA2677517C (en) | Nucleic acid-based tests for rhd typing, gender determination and nucleic acid quantification | |
| US8394582B2 (en) | Identification of fetal DNA and fetal cell markers in maternal plasma or serum | |
| CN103534591B (zh) | 通过测序分析进行的非侵入性胎儿遗传筛选 | |
| CN101971178B (zh) | 核酸序列失衡的确定 | |
| Delahunty et al. | Testing the feasibility of DNA typing for human identification by PCR and an oligonucleotide ligation assay | |
| US11542556B2 (en) | Single nucleotide polymorphism in HLA-B*15:02 and use thereof | |
| GB2488358A (en) | Enrichment of foetal DNA in maternal plasma | |
| EP2010676A1 (en) | Method and kit for molecular chromosomal quantification | |
| CA2909479A1 (en) | Method of determining the fraction of fetal dna in maternal blood using hla markers | |
| CN106939334A (zh) | 一种孕妇血浆中胎儿dna含量的检测方法 | |
| KR101761801B1 (ko) | 코 표현형 판단용 조성물 | |
| WO2016008550A1 (en) | Non-invasive early detection of solid organ transplant rejection by quantitative analysis of hla gene amplicons | |
| US20060084095A1 (en) | Compositions, methods, and systems for determining bovine parentage and identity | |
| JP6245796B2 (ja) | 原発性胆汁性肝硬変の発症リスク予測マーカー、プローブ、プライマー及びキット並びに原発性胆汁性肝硬変の発症リスク予測方法 | |
| CN104024410A (zh) | Hla-a*24组的判定方法 | |
| US20140037549A1 (en) | Genetic markers for prognosis of rheumatoid arthritis treatment efficacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20151014 |
|
| FZDE | Discontinued |
Effective date: 20190122 |
|
| FZDE | Discontinued |
Effective date: 20190122 |